Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa PM1032 in advanced solid tumors
ChiCTR2200060628Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PM1032 in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 5 more, sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicity within 21 days after first administration, Treatment-related adverse events and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
PM1032
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200060628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060628.